Related references
Note: Only part of the references are listed.Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain
Yoshihiro Kobashigawa et al.
GENES TO CELLS (2016)
Illuminating the Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance for the FGFR1 Gatekeeper Mutation: The Achilles' Heel of Targeted Therapy
Christal D. Sohl et al.
ACS CHEMICAL BIOLOGY (2015)
Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain
Yoshihiro Kobashigawa et al.
GENES TO CELLS (2015)
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
Tobias Klein et al.
NATURE COMMUNICATIONS (2015)
The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study
Tom D. Bunney et al.
EBIOMEDICINE (2015)
DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
Zhifeng Huang et al.
ACS CHEMICAL BIOLOGY (2015)
Structural Analysis of the Human Fibroblast Growth Factor Receptor 4 Kinase
E. Lesca et al.
JOURNAL OF MOLECULAR BIOLOGY (2014)
Structural Insights into FGFR Kinase Isoform Selectivity: Diverse Binding Modes of AZD4547 and Ponatinib in Complex with FGFR1 and FGFR4
Julie A. Tucker et al.
STRUCTURE (2014)
Receptor Tyrosine Kinases: Legacy of the First Two Decades
Joseph Schlessinger
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
S. Yoshikawa et al.
ONCOGENE (2013)
Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
V. Chell et al.
ONCOGENE (2013)
The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors
Sara A. Byron et al.
NEOPLASIA (2013)
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm
Don L. Gibbons et al.
CANCER (2012)
Targeting Fibroblast Growth Factor Receptor Signaling Inhibits Prostate Cancer Progression
Shu Feng et al.
CLINICAL CANCER RESEARCH (2012)
Structural Mechanism of the Pan-BCR-ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance
Tianjun Zhou et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Crizotinib-Resistant Mutants of EML4-ALK Identified Through an Accelerated Mutagenesis Screen
Sen Zhang et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2011)
Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression
G. Chen et al.
BRITISH JOURNAL OF CANCER (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Mohammad Azam et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2008)
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Cai-Hong Yun et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases
Huaibin Chen et al.
MOLECULAR CELL (2007)
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor β gatekeeper mutants
Teresa Guida et al.
CLINICAL CANCER RESEARCH (2007)
The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability
Frank H. Niesen et al.
NATURE PROTOCOLS (2007)
Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins
M Koziczak et al.
ONCOGENE (2004)
Protein kinase inhibitors: Insights into drug design from structure
MEM Noble et al.
SCIENCE (2004)
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors
S Blencke et al.
CHEMISTRY & BIOLOGY (2004)
Protein kinases - the major drug targets of the twenty-first century?
P Cohen
NATURE REVIEWS DRUG DISCOVERY (2002)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
Share Paper
